<DOC>
	<DOCNO>NCT02612779</DOCNO>
	<brief_summary>Study elotuzumab combination pomalidomide low dose dexamethasone ( EPd Cohort ) elotuzumab combination nivolumab ( EN Cohort ) ass safety efficacy combination therapy treatment relapse refractory MM patient .</brief_summary>
	<brief_title>A Study Elotuzumab Combination With Pomalidomide Low Dose Dexamethasone Elotuzumab Combination With Nivolumab Patients With Multiple Myeloma Relapsed Refractory Prior Treatment With Lenalidomide .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com 1 . All subject must document disease progression per IMWG criterion last antimyeloma therapy . 2 . ECOG Performance Status less equal 2 3 . Subject Reenrollment : This study permit reenrollment subject discontinue study pretreatment failure ( ie , treat ) . If reenrolled , subject must reconsented . 4 . EPd Cohort : must receive least 1 great 2 prior line therapy ( note : induction stem cell transplant without maintenance therapy consider 1 line therapy ) Subjects must receive prior treatment lenalidomidecontaining regimen least 2 consecutive cycle ( full therapeutic dose ) must deem relapsed , refractory , intolerant . Refractory define progress ontreatment within 60 day last dose . 5 . EN Cohort : Subjects must receive least 3 prior line therapy include proteasome inhibitor ( PI ) immunomodulatory ( IMID ) agent OR doublerefractory IMID PI . Refractory define progress ontreatment within 60 day last dose . 1 . Subjects solitary bone extramedullary plasmacytoma evidence plasma cell dyscrasia 2 . Subjects monoclonal gammopathy undetermined significance ( MGUS ) , smolder multiple myeloma ( SMM ) , primary amyloidosis , Waldenstrom 's macroglobulinemia , POEMS syndrome ( plasma cell dyscrasia poly neuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 3 . Subjects Central Nervous System involvement multiple myeloma Other protocol define inclusion/exclusion criterion could apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>